Anionos Aminos CJC Ipamorelin refers to a synthesized research peptide formulation combining CJC-1295 (a GHRH analog) and Ipamorelin (a selective ghrelin receptor agonist) for laboratory research use only. Investigated in preclinical models, this dual-peptide combination evaluates complementary growth hormone secretagogue pathways to promote selective, pulsatile pituitary secretion without significant cortisol or prolactin elevation.
Anionos Aminos CJC Ipamorelin refers to a synthesized research peptide formulation combining CJC-1295 (a GHRH analog) and Ipamorelin (a selective ghrelin receptor agonist) for laboratory research use only. Investigated in preclinical models, this dual-peptide combination evaluates complementary growth hormone secretagogue pathways to promote selective, pulsatile pituitary secretion without significant cortisol or prolactin elevation.
In contemporary bio-molecular research, terms such as 'Anionos Aminos CJC Ipamorelin' refer to specialized co-formulations or individual reference standards of growth hormone secretagogues (GHS) utilized in laboratory settings. These formulations integrate two distinct peptide sequences: CJC-1295 (a synthetic analog of growth hormone-releasing hormone, GHRH) and Ipamorelin (a pentapeptide selective growth hormone secretagogue receptor agonist). By combining these two distinct molecular structures, investigators can examine how concurrent receptor binding influences anterior pituitary signaling in cell cultures and animal models.
When sourcing high-purity compounds for analytical or in vitro research, investigators require strictly tested reference materials. PX1 Research provides fully characterized, USA-manufactured research peptides to ensure batch-to-batch consistency. The combination of CJC-1295 and Ipamorelin allows researchers to investigate two separate signal transduction cascades simultaneously, offering insights into how GHRH receptor stimulation and ghrelin receptor activation interact at the cellular level.
The primary scientific interest in the CJC-1295 and Ipamorelin pair lies in their distinct, non-overlapping mechanisms of action at the pituitary level. CJC-1295 acts directly as an agonist at the growth hormone-releasing hormone receptor (GHRH-R). Upon binding, it stimulates adenylate cyclase, increasing intracellular cyclic adenosine monophosphate (cAMP) and activating protein kinase A (PKA). This cascade triggers the transcription and exocytosis of growth hormone (GH) stored within somatotropes.
Conversely, Ipamorelin functions as a selective agonist of the growth hormone secretagogue receptor 1a (GHSR-1a), also known as the ghrelin receptor. Activation of GHSR-1a initiates a phospholipase C (PLC)-dependent signal transduction pathway, leading to the generation of inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers the release of intracellular calcium from the endoplasmic reticulum. Preclinical studies suggest that when GHRH-R (stimulated by CJC-1295) and GHSR-1a (stimulated by Ipamorelin) are engaged simultaneously, the intracellular cAMP and calcium signaling pathways converge. This convergence yields a synergistic increase in somatotroph responsiveness, resulting in a significantly greater physiological release of GH than either agonist achieves independently.
A key parameter in growth hormone secretagogue research is receptor selectivity. First- and second-generation secretagogues frequently induce off-target pituitary activation, leading to elevated plasma levels of adrenocorticotropic hormone (ACTH), cortisol, and prolactin. Elevated cortisol and prolactin can confound experimental results in metabolic, tissue regeneration, and body composition studies.
In vitro data and rodent models indicate that Ipamorelin exhibits an unusually high level of receptor specificity. Even at high concentration thresholds in preclinical models, Ipamorelin demonstrates minimal to no affinity for receptors modulating ACTH or prolactin secretion. When paired with CJC-1295 (without DAC, or tetrasubstituted modified GRF 1-29), the resulting endocrine response remains targeted strictly to the somatotropic axis. This clean selectivity profile enables researchers to analyze endogenously stimulated, pulsatile growth hormone release without interference from stress-hormone signaling pathways or galactopoietic pathways.
Understanding secretagogue kinetics is essential for designing rigorous laboratory experiments. Natural growth hormone release in mammalian models occurs in a pulsatile, episodic fashion. Sustained, tonic elevation of GH can lead to down-regulation of pituitary receptors, altered insulin sensitivity, and receptor desensitization.
In research studies utilizing CJC-1295 No DAC and Ipamorelin, the combination demonstrates rapid wash-in and wash-out kinetics. Modified GRF 1-29 provides a transient half-life (~30 minutes) that mimics the physiological pulse of native GHRH, while Ipamorelin provides a short, defined GH peak lasting approximately 2 hours. This dual profile induces a sharp, robust GH pulse followed by a return to baseline, preserving the natural sensitivity of pituitary somatotropes and target organ IGF-1 receptors during longitudinal preclinical trials.
To select the appropriate secretagogue for a specific protocol, researchers often evaluate how the CJC-1295 / Ipamorelin pairing compares against alternative compounds within the growth hormone secretagogue class. Key comparative options evaluated in the literature include Sermorelin, GHRP-2, and MK-677.
While Sermorelin targets the GHRH receptor similarly to CJC-1295, its shorter baseline half-life (~8–12 minutes) requires rapid clearance modeling. GHRP-2 is a potent GHSR-1a agonist but reliably induces moderate spikes in cortisol and prolactin, along with marked increases in appetite signaling via central ghrelin pathways. Non-peptide oral secretagogues like MK-677 offer long-term GH and IGF-1 elevation over 24-hour periods, but lack the precise, pulsatile control afforded by the short-acting CJC-1295 / Ipamorelin combination. Consequently, for assays focused on clean, episodic GH release, the CJC-1295 / Ipamorelin pairing remains the preferred reference standard.
In vitro and animal model studies evaluating GHRH/GHRP dual therapy span several major domains of biological research:
1. Protein Synthesis and Nitrogen Balance: Preclinical trials examine how stimulated GH pulses upregulate hepatic Insulin-like Growth Factor 1 (IGF-1) transcription, promoting amino acid transport and myofibrillar protein accretion in muscular tissue models. 2. Lipid Metabolism: Research models utilize secretagogue combinations to analyze lipolysis in adipocyte cultures, observing changes in hormone-sensitive lipase (HSL) activity and non-esterified fatty acid mobilization. 3. Bone and Connective Tissue Remodeling: In rodent models of osteopenia, dual secretagogue administration is studied for its capacity to activate osteoblast proliferation and enhance collagen cross-linking in collagenous matrices. 4. Cellular Repair Mechanisms: In vitro culture assays evaluate how localized IGF-1 induction downstream of GH secretagogue exposure influences mitochondrial efficiency, cell migration, and wound healing kinetics.
When purchasing compounds labeled under terms like Anionos Aminos or sourcing custom research peptides, laboratory personnel must rigorously verify reagent purity. Substandard or contaminated peptide preparations introduce uncontrollable variables into cell culture and animal models, compromising data integrity.
PX1 Research adheres to stringent quality control criteria for all catalog compounds:
- High-Performance Liquid Chromatography (RP-HPLC): Every production lot undergoes reverse-phase HPLC to confirm chemical purity exceeding 98.0%. This verifies the absence of truncated sequences, deletion peptides, or synthesis byproducts. - Mass Spectrometry (MS): Electrospray ionization mass spectrometry (ESI-MS) or MALDI-TOF is conducted per lot to verify precise molecular weight and sequence identity. - Endotoxin Quantification: Preclinical reagents must meet strict endotoxin thresholds. PX1 products are tested via Chromogenic LAL assay to guarantee endotoxin levels below 0.005 EU/mg, preventing lipopolysaccharide-induced inflammatory responses in sensitive cell lines or rodent models. - Batch Traceability & Documentation: Every order is accompanied by a lot-specific Certificate of Analysis (COA) issued by an independent ISO 17025 accredited laboratory.
Proper reconstitution and handling protocols are vital to preserve peptide stability and prevent degradation via oxidation or aggregation during laboratory experimentation.
Lyophilized Storage: Solid lyophilized cake should be stored in a dark, desiccated freezer environment at -20°C to -80°C. Under these conditions, the peptide matrix remains stable for extended periods.
Reconstitution Procedures: Under laminar flow, allow the vial to reach room temperature before adding sterile bacteriostatic water (0.9% benzyl alcohol) or sterile research-grade phosphate-buffered saline (PBS). Direct the solvent along the inner glass wall of the vial rather than shooting it directly onto the lyophilized powder. Gently swirl the vial until dissolved; never vortex or vigorously shake, as mechanical shear stress can disrupt secondary peptide structures.
Aliquoting and Storage: Once reconstituted, store the liquid solution at 2°C to 8°C for short-term experimental series (up to 30 days). For long-term usage, divide the solution into single-use micro-centrifuge tubes and freeze at -80°C to avoid repeated freeze-thaw cycles.
Securing compliant, analytical-grade reference compounds is essential for institutional research facilities, university laboratories, and private biotech firms. Evaluating vendors requires verifying US-based manufacturing, state-of-the-art synthesis infrastructure, and complete transparency.
PX1 Research supplies USA-manufactured research peptides designed strictly for laboratory use. Facilities interested in high-volume testing or customized assay requirements can access tailored support through our wholesale lab account portal. Additional protocol references, stability literature, and mechanistic summaries are detailed across our institutional research library hub.
What is 'Anionos Aminos CJC Ipamorelin' in a research context?
It refers to research-grade formulations combining CJC-1295 (a GHRH analog) and Ipamorelin (a selective GHRP). This combination is used in laboratory settings to study dual-receptor activation of the growth hormone axis.
What receptors do CJC-1295 and Ipamorelin target in laboratory models?
CJC-1295 acts as an agonist at the Growth Hormone-Releasing Hormone Receptor (GHRH-R), while Ipamorelin selectively targets the Growth Hormone Secretagogue Receptor 1a (GHSR-1a, or ghrelin receptor).
Does Ipamorelin elevate cortisol or prolactin in preclinical studies?
No. Preclinical data show that Ipamorelin is highly selective for GHSR-1a and does not significantly stimulate ACTH, cortisol, or prolactin secretion, distinguishing it from older secretagogues like GHRP-2 or GHRP-6.
How is the purity of PX1 Research peptides verified?
Every lot undergoes independent ISO 17025 laboratory testing, including Reverse-Phase HPLC to confirm >98% purity, Mass Spectrometry for sequence verification, and Chromogenic LAL assays for endotoxin measurement.
What solvent is recommended for reconstituting CJC-1295 / Ipamorelin for in vitro assays?
Reconstitution is typically performed using sterile bacteriostatic water (0.9% benzyl alcohol) or sterile research-grade PBS, handled under aseptic laminar flow conditions.
What is the endotoxin limit for PX1 Research compounds?
PX1 Research guarantees endotoxin levels below 0.005 EU/mg per batch, preventing cell culture contamination or pyrogenic responses in animal models.
How should reconstituted peptide solutions be stored in the lab?
Reconstituted solutions should be kept at 2°C to 8°C for short-term use (up to 30 days) or aliquoted into single-use tubes and stored at -80°C to prevent freeze-thaw degradation.
Is CJC-1295 / Ipamorelin approved for human consumption or medical therapy?
No. All products sold by PX1 Research are strictly for laboratory research, in vitro assays, and preclinical experimentation. They are never for human, clinical, or therapeutic use.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.